FDA Office Of Drug Safety “Separate But Unequal” To Office Of New Drugs, Senate Inquiry Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
Finance Committee Chairman Grassley’s investigation into FDA’s handling of pediatric suicidality concerns with antidepressant drugs reveals ODS “serves a subservient” role to OND. Grassley points to allegations that OND discourages recommendations in drug consults.
You may also be interested in...
Sen. Grassley Targets FDA's Handling Of Adderall XR Adverse Events
Finance Committee chairman expresses concern that agency may have sought to dissuade Health Canada from suspending Adderall XR sales because "FDA could not handle another 'drug safety crisis.'" Grassley requests records of FDA's meetings with Health Canada.
Sen. Grassley Targets FDA's Handling Of Adderall XR Adverse Events
Finance Committee chairman expresses concern that agency may have sought to dissuade Health Canada from suspending Adderall XR sales because "FDA could not handle another 'drug safety crisis.'" Grassley requests records of FDA's meetings with Health Canada.
FDA’s Drug Safety Office Is Already Independent, CDER Director Says
Acting CDER Director Galson responds to calls for greater independence of drug safety functions by noting that both the Office of Drug Safety and Office of New Drugs report directly to him. FDA will “continue its longstanding practice of assessing the safety of all drugs” using “sound science,” Galson says.